전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
≥72% 7...8 aastastest uuritavatest.
≥72% of subjects 7-8 years of age.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
vereülekannet ei saanud ükski uuritavatest.
no subject received a blood transfusion.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
valitav protseduur sõltub uuritavatest aminohapetest.
the procedure chosen depends on the amino acids under investigation.
마지막 업데이트: 2014-11-21
사용 빈도: 3
품질:
kõik raviga seotud kõrvalnähud ≥ 5% uuritavatest.
all treatment-emergent adverse events with ≥ 5% of subjects
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
juhtum tekkis vähem kui pooltel ohustatud uuritavatest.
fewer than half of at-risk subjects had an event.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
kõikides vanuserühmades teatati palavikust vähesel protsendil uuritavatest.
across all ages, low percentages of subjects reported fever.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
südame paispuudulikkust täheldati 0,5 % uuritavatest kummaski ravirühmas.
congestive heart failure was observed in 0.5% of subjects in each treatment arm.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
kokku 54%-l uuritavatest oli ravieelselt vähem kui 3 haiguskollet.
overall, 54% of subjects had <3 disease sites at baseline.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
경고: 보이지 않는 HTML 형식이 포함되어 있습니다
kõik raviga seotud tõsised kõrvalnähud 1% lenalidomiidiga ravitud uuritavatest
all treatment-emergent serious adverse events in 1% of lenalidomide treated subjects
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
korea valitsuse ja citibanki korral ulatusid need kaugemale uuritavatest laenudest.
for the gok and citibank these went beyond the loans investigated.
마지막 업데이트: 2014-11-21
사용 빈도: 1
품질:
umbes ühel protsendil uuritavatest toimus losartaani minimaalne konversioon aktiivseks metaboliidiks.
minimal conversion of losartan to its active metabolite was seen in about one percent of individuals studied.
마지막 업데이트: 2012-04-11
사용 빈도: 2
품질:
düspnoest teatati ligikaudu 30% uuritavatest kyprolis’e kliinilistes uuringutes.
dyspnoea was reported in approximately 30% of subjects in clinical studies with kyprolis.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
reas farmakokineetilistes ja kliinilistes uuringutes saavutasid 6% uuritavatest kõrgema desloratadiini kontsentratsiooni.
in a series of pharmacokinetic and clinical trials, 6% of the subjects reached a higher concentration of desloratadine.
마지막 업데이트: 2012-04-11
사용 빈도: 5
품질:
uuritavatest ainetest valmistatakse vajaliku kontsentratsiooniga vesilahused, kuhu ei tohi jääda lahustumatut jääki.
aqueous solutions shall be prepared of the substances to be tested, using the required concentrations in water, and shall not contain any non-dissolved substances.
마지막 업데이트: 2014-11-21
사용 빈도: 3
품질:
skisofreenia kliinilistes uuringutes täheldati invega puhul seerumi prolaktiinisisalduse suurenemist 67% uuritavatest.
in schizophrenia clinical trials, increases in serum prolactin were observed with invega in 67% of subjects.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
tehti kindlaks, et uurimisperioodi jooksul kasutase seda kava üks uuritavatest eksportijatest, kes tegutses gujaratis.
it was established that one exporter under investigation, which is situated in gujarat, used this scheme during the review investigation period.
마지막 업데이트: 2014-11-21
사용 빈도: 1
품질:
alfaepoetiiniga ravitud ≥ 1% uuritavatest esinenud kõrvaltoimed neis uuringutes on toodud allolevas tabelis.
adverse drug reactions reported by ≥ 1% of subjects treated with epoetin alfa in these trials are shown in the table below.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
ligikaudu 40%-l ravitud uuritavatest esines süsteemseid kõrvalnähte ja ligikaudu 54%-l reaktsioone süstekohal.
approximately 40% of treated subjects experienced systemic adverse reactions and approximately 54% experienced injection site reactions.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
mõningate ühendite puhul võib suure kontsentratsiooniga uuritavatest doosidest keeldumine põhjustada selle, et toitu tarbitakse vähe või üldse mitte.
for some compounds, at higher concentrations rejection of test dose may result in little or no food being consumed.
vaktsiinigrupis olid kolmanda annuse manustamise järgse kuu jooksul muutunud kõikidele vaktsiini serotüüpidele seropositiivseks 99,1 kuni 100% uuritavatest.
in the vaccine group, 99.1 to 100% became seropositive to all vaccine serotypes by 1 month postdose 3.